ストックスクリーナーアプリを入手
1.90
97.92%
0.94
アフターアワーズ：
2.06
0.16
+8.42%
前日終値:
$0.96
開ける：
$1.09
24時間の取引高:
14.11M
Relative Volume:
38.78
時価総額：
$11.45M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
+110.51%
1か月 パフォーマンス:
+206.70%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$1.00
$2.45
1週間の範囲:
$0.81
$2.45
52週間の値動き範囲:
$0.45
$2.45
Chromocell Therapeutics Corp Stock (CHRO) Company Profile
名前
Chromocell Therapeutics Corp
セクター
電話
(917) 644-6313
住所
685 US HIGHWAY ONE, NORTH BRUNSWICK
CHRO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CHRO
Chromocell Therapeutics Corp
|
1.90 | 11.45M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
Chromocell Therapeutics Corp (CHRO) 最新ニュース
Biopharma IPOs rebound slightly, as class of 2024 lags with a 29% average decline - BioWorld Online
Channel Therapeutics Advances Novel Pain Treatment Strategy with NaV1.7 Inhibitor Pipeline - StockTitan
Channel Therapeutics' Pain Treatment Breakthrough: Novel Nerve Block Outperforms Standard Care in Key Trial - StockTitan
Channel Therapeutics Announces Positive Efficacy Data For a Depot Formulation of a NaV1.7 Inhibitor in a Preclinical In Vivo Nerve Block Model - Quantisnow
Chromocell Therapeutics Announces Name Change to Channel Therapeutics Corporation and Provides Therapeutic Program Updates - Defense World
Chromocell Announces Name Change to 'Channel Therapeutics Corporation” and Provides Therapeutic Program Updates - The Manila Times
Chromocell changes name to Channel Therapeutics, provides program updates - TipRanks
Channel Therapeutics Corporation Provides Therapeutic Program Update - Marketscreener.com
Chromocell Therapeutics Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 - Marketscreener.com
Certain Warrants of Chromocell Therapeutics Corporation are subject to a Lock-Up Agreement Ending on 16-AUG-2024. - Marketscreener.com
Chromocell Therapeutics Corporation announces an Equity Buyback for $0.25 million worth of its shares. - Marketscreener.com
Chromocell Therapeutics Corporation Announces Unveiling of Injectable Depot Program for the Treatment of Surgical Pain - Marketscreener.com
Certain Common Stock of Chromocell Therapeutics Corporation are subject to a Lock-Up Agreement Ending on 16-AUG-2024. - Marketscreener.com
Certain Series A Preferred Stock of Chromocell Therapeutics Corporation are subject to a Lock-Up Agreement Ending on 16-AUG-2024. - Marketscreener.com
Chromocell Therapeutics Corporation announced that it expects to receive $0.75 million in funding - Marketscreener.com
Chromocell to Present at Sidoti Virtual Investor Conference March 13-14 - Marketscreener.com
Chromocell Therapeutics Corporation Announces Formal Launch of Eye Pain Treatment Program - Marketscreener.com
Chromocell Therapeutics Corporation announced that it has received $0.75 million in funding - Marketscreener.com
Chromocell Therapeutics Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Channel Therapeutics Advances Non-Opioid Pain Programs, Reports 96-Hour Drug Release Success - StockTitan
Channel Therapeutics announces corporate restructuring By Investing.com - Investing.com Australia
Channel Therapeutics announces corporate restructuring - Investing.com India
Channel Therapeutics finalizes corporate restructuring By Investing.com - Investing.com Canada
Channel Therapeutics finalizes corporate restructuring - Investing.com
Chromocell Announces Unveiling of Injectable Depot Program for the Treatment of Surgical Pain - The Manila Times
Chromocell to Present at Upcoming Fall Investor Conferences - The Manila Times
Chromocell announces amendment to stock repurchase plan - MSN
Chromocell Therapeutics amends stock repurchase plan - TradingPedia
Chromocell boosts stock buyback plan to $750,000 - Investing.com India
Chromocell Announces Amendment to Stock Repurchase Plan - The Manila Times
Chromocell boosts stock buyback plan to $750,000 By Investing.com - Investing.com South Africa
Chromocell Announces Amendment to Stock Repurchase Plan | CHRO Stock News - StockTitan
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Upward Trajectory: Chromocell Therapeutics Corp. (CHRO) Posts a Slidee, Closing at 0.84 - The Dwinnex
CHRO’s Market Quandary: Decoding the Ups and Downs of 2023 - The InvestChronicle
Chubb (CB) Stock Declines While Market Improves: Some Information for Investors - Yahoo Finance
Stocks of Chemours Company (CC) are poised to climb above their peers - SETE News
Chubb Limited [CB] stock was sold by GREENBERG EVAN G at the price of US$8.78 million - Knox Daily
Recent 4.1% pullback isn't enough to hurt long-term Calumet (NASDAQ:CLMT) shareholders, they're still up 373% over 5 years - Yahoo Finance
Calumet Specialty Products Partners (NASDAQ:CLMT) Shares Gap Down to $18.00 - Defense World
Market Update: Calumet Inc. (CLMT) Sees Negative Movement, Closing at 18.00 - The Dwinnex
C.H. Robinson Worldwide Sees Unusually High Options Volume (NASDAQ:CHRW) - MarketBeat
CHRS stock touches 52-week low at $1.01 amid market challenges - Investing.com India
CG Oncology initiated with an Outperform at RBC Capital - TipRanks
Comparing BioLargo (NASDAQ:BLGO) and Chemours (NYSE:CC) - Defense World
Chubb Stock Trading Near 52-Week High: What Should Investors Know? - Yahoo Finance
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing - Morningstar
Choreo LLC Purchases New Stake in C.H. Robinson Worldwide, Inc. (NASDAQ:CHRW) - Defense World
Cosmic CRF shares hit 5% upper circuit on Rs 127-crore order win; details - Business Standard
CorMedix stock soars to 52-week high, hits $7.29 By Investing.com - Investing.com Australia
Chromocell Therapeutics Corp (CHRO) 財務データ
Chromocell Therapeutics Corp (CHRO) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
0.65%
4.62%
大文字化:
|
ボリューム (24 時間):